Trial Profile

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 07 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Migalastat (Primary)
Indications Fabry's disease
Focus Adverse reactions; Registrational
Sponsors Amicus Therapeutics; GlaxoSmithKline; GSK

Most Recent Events

01 Jul 2023 Results of pooled post hoc analysis from FACETS, ATTRACT study, open-label extension (OLE) studies (AT1001-041), AT1001-042 published in the Journal of Medical Genetics
01 Oct 2018 Status changed to discontinued.
25 Aug 2017 According to an Amicus Therapeutics media release, data will be presented at the 13th International Congress of Inborn Errors of Metabolism 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com